ProBiotix Health Plc

Management Reports • Sep 16, 2024

National Storage Mechanism | Additional information

RNS Number : 1743E

Probiotix Health PLC

16 September 2024

16 September 2024

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

New Commercial Partnership in Greece

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Greece based consumer brands specialist Eifron SA ("Eifron").

As part of the terms of the agreement, Eifron will introduce YourBiotixBP tablets, containing LP LDL ®, under its existing probiotic consumer brand, with the anticipated product launch expected to be in Q1 2025. Through this strategic partnership, Eifron will expand its own portfolio by including a product for cholesterol and blood pressure lowering based on LP LDL ®. The addition of other products from the ProBiotix portfolio will be evaluated by the parties on an ongoing basis.  

ProBiotix Health has received a purchase order from Eifron, with the first sales planned for Greece and thereafter in selected regions in Europe.

Founded in 2011, Eifron specialises in innovative healthcare solutions and holds a strong market position, particularly in Greece where it is among the top five brands in the country. Its core focus is addressing unmet medical needs by developing and distributing advanced product solutions for the health sector, with particularly close ties among pharmacies and healthcare professionals. The current Eifron product portfolio includes pharmaceuticals, supplements, and medical devices.

Steen Andersen, CEO of ProBiotix, commented: " This exceptional opportunity to work with a science driven market leader like Eifron represents another significant milestone in our efforts to expand our reach and broaden the availability of our innovative cardiometabolic health product solutions in Europe.

"Eifron's reputation and expertise in the health sector and their commitment to natural solutions makes them an ideal partner for us."

Elias Kartasiadis, CEO of Eifron, added : "We are thrilled to partner with ProBiotix Health and bring their scientifically-backed products to our markets. This partnership aligns perfectly with our mission to provide our customers with effective and natural health solutions.

"We believe this collaboration will help us expand our reach and offer differentiation and added value to the growing group of consumers looking to improve their cardiometabolic health."

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) Mark Anwyl		Tel: 020 7220 9793
Walbrook PR Ltd                                                                              Anna Dunphy	[email protected] Mob: 07876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXBBGDCRDBDGSX